Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

被引：2

作者：

Zhu, Viola Weijia

Bestvina, Christine M.

Lopes, Gilberto

Hamm, John Turner

Johnson, Melissa Lynne

Lammers, Philip Edward

Le, Xiuning

Marathe, Omkar

Raez, Luis E.

Rao, Suman

Sabari, Joshua K.

Scheff, Ronald J.

Tapan, Umit

Thompson, Jonathan Robert

Karachaliou, Niki

Ellers-Lenz, Barbara

Brutlach, Sabine

Smit, Egbert F.

Wu, Yi-Long

机构：

[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[4] Norton Canc Inst PARENT, Louisville, KY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Baptist Canc Ctr, Memphis, TN USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Innovat Clin Res Inst, Anaheim, CA USA

[9] Mem Healthcare Syst, Hollywood, FL USA

[10] Medstar Franklin Sq Clin Res Ctr, Baltimore, MD USA

[11] NYU Langone Clin Canc Ctr, New York, NY USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA

[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[15] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[16] Merck KGaA, Dept Biostat, Darmstadt, Germany

[17] Merck KGaA, Darmstadt, Germany

[18] Netherlands Canc Inst, Amsterdam, Netherlands

[19] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS9136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9136

引用

下载

页数：3

共 50 条

[21] Tepotinib plus gefitinib in patients with EGFR-mutant NSCLC with MET amplification (METamp): final analysis of INSIGHT
Liam, Chong Kim
Ahmad, Azura Rozila
Hsia, Te-Chun
Zhou, Jianying
Kim, Dong-Wan
Cheng, Ying
Lu, Shun
Shin, Sang Won
Yang, James Chih-Hsin
Zhang, Yiping
Zhao, Jun
Bruns, Rolf
Johne, Andreas
Wu, Yi-Long
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 177 - 177
[22] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
Ahn, M.
Cantarini, M.
Frewer, P.
Hawkins, G.
Peters, J.
Howarth, P.
Ahmed, G.
Sahota, T.
Hartmaier, R.
Li-Sucholeiki, X.
Oxnard, G.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
[23] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
de Garibay, G. Ruiz
Roch, B.
Garrido Lopez, P.
Isla, D.
Aguado, C.
Callejo Perez, A.
Marse Fabregat, R.
Garcia Campelo, M. R.
Blasco Cordellat, A.
Sanchez Torres, J. M.
Bernabe Caro, R.
Juan Vidal, O. J.
Carpeno, J. De Castro
Franco, F. F.
Ramos Garcia, I.
Gomez Rueda, A.
Conde Gallego, E.
Ponce Aix, S.
Paz-Ares, L.
Zugazagoitia, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016
[24] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
Shreeve, S. M.
Martinez, M.
Verheijen, R. B.
Xie, J.
Sun, T.
Haddish-Berhane, N.
Curtin, J. C.
Karkera, J.
Pang, D.
Roshak, A.
Knoblauch, R. E.
Patel, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
[25] Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Liam, Chong Kin
Ahmad, Azura Rozila
Hsia, Te-Chun
Zhou, Jianying
Kim, Dong-Wan
Soo, Ross Andrew
Cheng, Ying
Lu, Shun
Shin, Sang Won
Yang, James Chih-Hsin
Zhang, Yiping
Zhao, Jun
Berghoff, Karin
Bruns, Rolf
Johne, Andreas
Wu, Yi-Long
CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1879 - 1886
[26] Phase II study of erlotinib plus onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
Sakai, Hiroshi
Kishi, Kazuma
Seto, Takashi
Kozuki, Toshiyuki
Nishio, Makoto
Imamura, Fumio
Nokihara, Hiroshi
Satouchi, Miyako
Tahata, Takashi
Nakagawa, Kazuhiko
ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
[27] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
Robinson, N. D.
Zhan, P.
Udelsman, B.
Boffa, D. J.
Goldberg, S. B.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
[28] Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib
Yu, Helena Alexandra
Kerr, Keith
Rolfo, Christian Diego
Fang, Jian
Finocchiaro, Giovanna
Wong, Kam-Hung
Veillon, Remi
Kato, Terufumi
Yang, James Chih-Hsin
Nadal, Ernest
Raskin, Jo
Le, Xiuning
Karachaliou, Niki
Ellers-Lenz, Barbara
OBrate, Aurora
Stroh, Christopher
Piske, Nadine
Boesler, Carsten
Yang, Jinji
Mazieres, Julien
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Wu, Yi-Long
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jin-Ji
Wislez, Marie
Huang, Cheng
Liam, Chong Kin
Mazieres, Julien
Tho, Lye Mun
Hayashi, Hidetoshi
Nhung, Nguyen Viet
Chia, Puey Ling
de Marinis, Filippo
Raskin, Jo
Zhou, Qinghua
Finocchiaro, Giovanna
Le, Anh Tuan
Wang, Jialei
Dooms, Christophe
Kato, Terufumi
Nadal, Ernest
Hin, How Soon
Smit, Egbert F.
Wermke, Martin
Tan, Daniel
Morise, Masahiro
O'Brate, Aurora
Adrian, Svenja
Pfeiffer, Boris M.
Stroh, Christopher
Juraeva, Dilafruz
Strotmann, Rainer
Goteti, Kosalaram
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Le, Xiuning
Kim, Tae Min
LANCET ONCOLOGY, 2024, 25 (08): : 989 - 1002
[30] The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
Chen, Kuan-Chih
Huang, Yen-Hsiang
Hsu, Kuo-Hsuan
Tseng, Jeng-Sen
Chang, Gee-Chen
Yang, Tsung-Ying
ONCOTARGETS AND THERAPY, 2023, 16 : 317 - 326

← 1 2 3 4 5 →